Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 1995

Study Completion Date

December 31, 2006

Conditions

Acromegaly

Interventions

DRUG

Octreotide-LAR

Trial Locations (1)

Department of Molecular and Clinical Endocrinology and Oncology University Federico II of Naples, Naples

All Listed Sponsors

lead

Federico II University

OTHER

NCT00461149 - Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly | Biotech Hunter | Biotech Hunter